Asunaprevir

Asunaprevir Struktur
630420-16-5
CAS-Nr.
630420-16-5
Englisch Name:
Asunaprevir
Synonyma:
CS-1413;BMS 650032;Asunaprevir;Asunaprevir API;Asunaprevir,≥98%;Asunaprevir USP/EP/BP;BMS 650032/Asunaprevir;Asunaprevir (BMS-650032);Asunaprevir (10mM in DMSO);BMS-650032; BMS 650032; BMS650032
CBNumber:
CB92614356
Summenformel:
C35H46ClN5O9S
Molgewicht:
748.29
MOL-Datei:
630420-16-5.mol

Asunaprevir Eigenschaften

Schmelzpunkt:
149-150oC
Dichte
1.37
storage temp. 
-20°C Freezer, Under inert atmosphere
Löslichkeit
DMSO (Slightly), Methanol (Slightly, Heated)
Aggregatzustand
Solid
pka
4.49±0.40(Predicted)
Farbe
White to Off-White
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Asunaprevir Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Sold under the trade name Sunvepra®, asunaprevir received approval in Japan as part of a combination treatment for the hepatitis C virus (HCV). Working in concert with daclatasvir (IX) (vide infra), asunaprevir is a unique treatment for HCV, as it is free from both interferon and ribavirin and is administered orally. This direct-acting anti-viral, which was developed by Bristol–Myers Squibb (BMS), works as an NS3/4A protease inhibitor, representing a valuable treatment option for patient populations who are unable to receive, or do not respond to, the standard course of treatment—peginterferon/ribavirin.

Enzyminhibitor

This highly selective HCV antiviral (FW = 748.29 g/mol; CAS 630420-16- 5; Symbol: ASV), also named BMS-650032, targets NS3 protease, a serine proteinase required for Hepatitis C Virus (HCV) polyprotein processing, showing good antiviral activity against replicons based on HCV Genotype 1a (EC50 = 4 nM), Genotype 1b (EC50 = 1.2 nM), Genotype 4 (EC50 = 1.8 nM), Genotype 5 (EC50 = 1.7 nM), and Genotype 6 (EC50 = 0.9 nM). It is far less effective against Genotype 2 (EC50 = 67 nM) and Genotype 3 (EC50 = >1100 nM). Asunaprevir is a peptidomimetic that occupies the active site, inhibiting the HCV NS3/4A serine protease, with little or no action against related viruses. The average Ki for ASV is approximately 0.4 nM and 0.2 nM for Genotype 1a and Genotype 1b, respectively. Its acylsulfonamide moeity interacts noncovalently with the NS3 protease – unlike telaprevir’s α-ketoamide moiety, which is linked covalently to NS3/4A’s catalytic serine and reverses slowly over time. ASV exhibits an excellent selectivity index (>40,000x) against all serine/cysteine proteases evaluated, including human leukocyte elastase, porcine pancreatic elastase, and three members of the chymotrypsin family. Although ASV shows a low barrier to resistance, it can be combined with daclatasvir to achieve a very high rate of viral eradication in both na?ve and treatment-experienced patients, showing a sustained virological response rate of 80%-90%.

Asunaprevir Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Asunaprevir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 149)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886
info@dakenam.com China 16220 58
Hubei XinRunde Chemical Co., Ltd.
+8615102730682
bruce@xrdchem.cn CHINA 566 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29901 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 967 58
Nanjing Dolon Biotechnology Co.,Ltd.
18905173768
sales@dolonchem.com CHINA 2972 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
Chongqing Chemdad Co., Ltd
+86-023-6139-8061 +86-86-13650506873
sales@chemdad.com China 39916 58
Hebei Binshare New Material Co. Ltd
+8618633865755
china01@hbbinshare.com CHINA 969 58
Nanjing Fred Technology Co., Ltd.
+86-02584696168 15380713688
Austin@fredchem.cn CHINA 865 58
Qiuxian Baitai New Material Co., LTD
+8618330912755
sale2@hbyalin.com China 1677 58

  • (1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide
  • Asunaprevir
  • BMS 650032
  • Asunaprevir (BMS-650032)
  • BMS 650032/Asunaprevir
  • Asunaprevir API
  • tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
  • BMS-650032; BMS 650032; BMS650032
  • CS-1413
  • tert-Butyl ((2S)-1-((2S)-2-(((1R,2S)-1-amino-2-vinylcyclopropane-1-carbonyl)(cyclopropylsulfonyl)carbamoyl)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
  • Asunaprevir,≥98%
  • Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)-
  • Asunaprevir USP/EP/BP
  • Asunaprevir (10mM in DMSO)
  • 630420-16-5
  • C35H46ClN5O9S
  • API
Copyright 2019 © ChemicalBook. All rights reserved